Bropirimine , ≥98%(HPLC) , 56741-95-8
Synonym(s):
2-amino-5-bromo-6-phenyl-4(3H)-pyrimidinone;NSC 149027;PNU 54461;U 54461;U 54461S
| Pack Size | Price | Stock | Quantity |
| 250mg | RMB191.20 | In Stock |
|
| 1g | RMB463.20 | In Stock |
|
| others | Enquire |
PRODUCT Properties
| Melting point: | 285-287° (Stevens); mp 246-248° (Brown, Stevens) |
| Boiling point: | 389.7±52.0 °C(Predicted) |
| Density | 1.6292 (rough estimate) |
| refractive index | 1.6520 (estimate) |
| storage temp. | room temp |
| solubility | DMSO: ≥5mg/mL (warm DMSO) |
| form | powder |
| pka | 3.18; 8.53(at 25℃) |
| color | white to beige |
| Water Solubility | 7.8mg/L(37 ºC) |
Description and Uses
Bropirimine is an immunomodulator with diverse biological activities. It is a toll-like receptor 7 (TLR7) agonist that inhibits RANKL-induced osteoclast differentiation of murine bone marrow-derived macrophages (BMDMs) in a concentration-dependent manner, an effect that is reversed by an anti-IFN-β antibody. Dietary administration of bropirimine (200 mg/kg twice per week) prevents development of transitional cell carcinomas (TCCs) in a mouse model of carcinogen-induced bladder carcinoma. Bropirimine (100 mg/kg) reduces pulmonary collagen accumulation and bronchoalveolar lavage fluid (BALF) monocyte and eosinophil infiltration in a hamster model of bleomycin-induced lung fibrosis. It also delays disease onset and progression and increases plasma IFN levels in a mouse model of experimental autoimmune encephalomyelitis (EAE).
Bropirimine is an orally active immunostimulant; anticancer agent. Bropirimine is an interferon inducer that is a potentially useful in the the treatment of superficial bladder cancer (transitional cell carcinoma). Studies suggest that Bropirimine has direct antitumor activity rather than a cytokine-mediated antitumor effect.
